Αποτελέσματα Αναζήτησης
The year provided represents the year of diagnosis. Share of adults (aged 15-99), and children (aged 0-14) for leukaemia, diagnosed with cancer who survive at least five years following their diagnosis date.
- Cancer Death Rate by Type
Five-year cancer survival rates by sex and race; Five-year...
- Cancer Death Rate by Type
30 Σεπ 2022 · In the period 2013–2017, people diagnosed with cancer were 64% as likely to survive for at least 10 years after being diagnosed compared to the corresponding population. 10-year relative survival ranged from 9% to 92% for the cancer types analysed.
7 Φεβ 2024 · Cancer statistics often use an overall five-year survival rate. Survival rates are usually given in percentages. For instance, the overall five-year survival rate for bladder cancer is 77%. That means that of all people who have bladder cancer, 77 of every 100 are living five years after diagnosis.
8 Μαΐ 2019 · IL-10 and IL-18 can be used as indicators to judge the prognosis of CRC patients, specifically the lower the expression levels of IL-10 and IL-18, the lower the recurrence rate of cancer, the better the prognosis and the longer the survival time.
16 Φεβ 2023 · Cancer survival varies by cancer site/group and by stage at diagnosis. The range in 5-year age-standardised net survival for all stages combined is from 11.8% (liver cancer for females) to 94.6% (melanoma of skin for females).
Among healthy adult volunteers serum IL-10 levels ranged from 4.8–9.8 pg/ml (mean 7.1, standard deviation 1.5 pg/ml). Therefore levels < 10 pg/ml were considered elevated. We identified 101 patients with available serum. Their median age was 32 years, and 60% had B-symptoms. Ann Arbor stage was I in 4, II in 21, III in 35, and IV in 41 patients.
Here, the authors review the literature surrounding the role of IL-10 within the tumor microenvironment, its prognostic correlates to cancer patient outcomes and its pro- and antitumor effects, and they assess the legitimacy of potential therapeutic strategies harnessing IL-10 by outlining the notable preclinical and clinical evidence to date.
